Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243862 · ClinicalTrials.gov registry record · Phase 2
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
A Phase 2 study of Colorectal Cancer Metastatic, sponsored by Treos Bio Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT05243862: Active Phase 2 study of Colorectal Cancer Metastatic, sponsored by Treos Bio Limited.
NCT05243862 is a Phase 2 study of Colorectal Cancer Metastatic that is active but no longer recruiting, run by Treos Bio Limited. The registered enrollment target is 18 participants, below the 204-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05243862, a Phase 2 study of Colorectal Cancer Metastatic, is active but no longer recruiting, sponsored by Treos Bio Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior regimens.
Primary Outcome
The incidence and severity \[according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0)\] of all Treatment-Emergent Adverse Events (TEAEs), related TEAEs, all SAEs, and related SAEs
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG PolyPEPI1018
Study Locations (3)
Arizona
- Mayo Clinic - Phoenix
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2026-06-02 |
| Phase | Phase 2 |
What the registry record for NCT05243862 still lists
NCT05243862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 204-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Colorectal Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05243862 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05243862 about?
NCT05243862 is a clinical study titled "Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.". This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior regimens.
What is the current status of trial NCT05243862?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-06-02. Estimated completion is 2026-06-02.
What conditions does trial NCT05243862 study?
This clinical trial studies the following conditions: Colorectal Cancer Metastatic.
What interventions are being tested in trial NCT05243862?
The interventions under investigation include: Atezolizumab (DRUG), PolyPEPI1018 (DRUG).
Who is sponsoring clinical trial NCT05243862?
This trial is sponsored by Treos Bio Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05243862 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05243862's enrollment target sits among peer trials
18 16th of 18 higher than 3 of 18 other Colorectal Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
RECRUITING · Phase 2
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
RECRUITING · Phase 2
-
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
RECRUITING · Phase 2
-
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
COMPLETED · Phase 2
-
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI